United States - English - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol-aq (cisplatin injection) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol-aq and cyclophosphamide. platinol-aq, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol-aq therapy. platinol-aq is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol-aq is contraindicated in patients with preexisting renal impairme

United States - English - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol (cisplatin for injection, usp) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol and cyclophosphamide. platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol therapy. platinol is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol is contraindicated in patients with preexisting renal impairment. plati

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh, kundl - oxaliplatino - oxaliplatino....50.00 mg. / oxaliplatino....100.00 mg.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

fresenius kabi oncology limited - oxaliplatino - oxaliplatino....5,00 mg

Canada - English - Health Canada

boiron laboratoires - platina homeo chemical - tablet - 4ch - platina homeo chemical 4ch - homeopathic products

Canada - English - Health Canada

boiron laboratoires - platina homeo chemical - drops - 4ch - platina homeo chemical 4ch - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - platina homeo chemical - tablet - 4ch - platina homeo chemical 4ch - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - platina homeo chemical - drops - 3ch - platina homeo chemical 3ch - homeopathic products

Canada - English - Health Canada

homeocan inc. - platina homeo chemical - tablet - 4ch - platina homeo chemical 4ch - homeopathic products

Australia - English - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - brivaracetam, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; purified water; methyl hydroxybenzoate; citric acid; glycerol; carmellose sodium; sorbitol solution (70 per cent) (crystallising); sucralose; flavour - briviact oral solution is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 4 years of age with epilepsy